Skip to main content

Table 1 Characteristics of all the eligible studies

From: LAPTM4B polymorphism increases susceptibility to multiple cancers in Chinese populations: a meta-analysis

First author Year Control source Cancer types Genotyping method Case/control HWE Case Control
        *1/1 *1/2 *2/2 *1/1 *1/2 *2/2
Sun 2008 PB Liver cancer PCR 190/175 0.587 72 110 8 99 67 9
Qi 2010 HB Liver cancer PCR 86/78 0.799 27 51 8 36 34 7
Zhai 2012 PB Hepatocellular carcinoma PCR 102/135   37 52 13    
Wang 2011 HB Primary liver cancer PCR 303/515 0.941 107 156 40 272 205 38
Deng 2005 HB Lung cancer PCR 162/134 0.285 54 91 21 67 59 8
Li 2006 PB Lung cancer PCR 131/104 0.155 70 56 5 57 36 11
Li 2012 HB Breast cancer PCR 208/211 0.185 90 100 18 129 76 6
Fan 2012 HB Breast cancer PCR 732/649 0.356 326 342 64 346 262 41
Yang 2012 PB Gallbladder carcinoma PCR 91/155 0.851 34 45 12 88 57 10
Wang 2013 HB Nasopharyngeal carcinoma PCR 134/327 0.07 74 48 12 163 145 19
Wang 2010 HB Pancreatic cancer PCR 58/156 0.977 24 26 8 74 67 15
Xu 2012 HB Ovarian cancer PCR 282/365 0.64 122 115 45 231 108 26
Meng 2011 HB Cervical carcinoma PCR 317/416 0.835 127 153 37 225 163 28
Meng 2013 HB Endometrial carcinoma PCR-RFLP 283/378 0.072 93 135 55 200 140 38
Liu 2007 HB Gastric cancer PCR 214/350 0.484 88 107 19 199 133 18
Cheng 2008 HB Colon/rectal/esophageal cancer PCR 701/350 0.484 362 293 46 199 133 18
Sun 2007 HB Lymphoma PCR 166/350 0.484 72 71 23 199 133 18
  1. HB hospital-based, PB population-based, HWE Hardy-Weinberg Equilibrium, PCR polymerase chain reaction, PCR-RFLP polymerase chain reaction–restriction fragment length polymorphism.